Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
- PMID: 27959628
- DOI: 10.1146/annurev-pathol-052016-100208
Signaling and Immune Regulation in Melanoma Development and Responses to Therapy
Abstract
Melanoma is a complex and genomically diverse malignancy, and new genes and signaling pathways involved in pathogenesis continue to be discovered. Mechanistic insights into gene and immune regulation in melanoma have led to the development of numerous successful and innovative pharmacologic agents over recent years. Multiple targeted therapies and immunotherapies have already entered the clinic, becoming new standards of care and transforming the prognosis for many patients with malignant melanoma. In this review, we provide an overview of the current understanding of signaling and immune regulation in melanoma and implications for responses to treatment, organized in the framework of hallmark characteristics in cancer.
Keywords: genomics; immunotherapy; melanocytes; pathogenesis; targeted therapy.
Similar articles
-
Novel immunotherapies for the treatment of melanoma.Immunotherapy. 2016 May;8(5):613-32. doi: 10.2217/imt-2015-0024. Immunotherapy. 2016. PMID: 27140413 Review.
-
Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.Pathology. 2016 Feb;48(2):194-202. doi: 10.1016/j.pathol.2015.12.010. Epub 2016 Jan 20. Pathology. 2016. PMID: 27020392 Review.
-
Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.Expert Rev Clin Immunol. 2014 Aug;10(8):1107-23. doi: 10.1586/1744666X.2014.929943. Epub 2014 Jun 17. Expert Rev Clin Immunol. 2014. PMID: 24939732 Review.
-
Interface of signal transduction inhibition and immunotherapy in melanoma.Cancer J. 2010 Jul-Aug;16(4):360-6. doi: 10.1097/PPO.0b013e3181eb3393. Cancer J. 2010. PMID: 20693848 Free PMC article. Review.
-
Toward prediction of immune mechanisms and design of immunotherapies in melanoma.Crit Rev Biomed Eng. 2012;40(4):279-94. doi: 10.1615/critrevbiomedeng.v40.i4.40. Crit Rev Biomed Eng. 2012. PMID: 23140120 Review.
Cited by
-
A Potential Diagnostic and Prognostic Biomarker TMEM176B and Its Relationship With Immune Infiltration in Skin Cutaneous Melanoma.Front Cell Dev Biol. 2022 Mar 23;10:859958. doi: 10.3389/fcell.2022.859958. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35399535 Free PMC article.
-
ImmReg: the regulon atlas of immune-related pathways across cancer types.Nucleic Acids Res. 2021 Dec 2;49(21):12106-12118. doi: 10.1093/nar/gkab1041. Nucleic Acids Res. 2021. PMID: 34755873 Free PMC article.
-
Development and Validation of a Combined Ferroptosis and Immune Prognostic Model for Melanoma.J Oncol. 2022 Nov 24;2022:1840361. doi: 10.1155/2022/1840361. eCollection 2022. J Oncol. 2022. PMID: 36467505 Free PMC article.
-
Pattern Recognition Receptors (PRRs) in Macrophages Possess Prognosis and Immunotherapy Potential for Melanoma.Front Immunol. 2021 Nov 9;12:765615. doi: 10.3389/fimmu.2021.765615. eCollection 2021. Front Immunol. 2021. PMID: 34858419 Free PMC article.
-
Prediction of clinical prognosis in cutaneous melanoma using an immune-related gene pair signature.Bioengineered. 2021 Dec;12(1):1803-1812. doi: 10.1080/21655979.2021.1924556. Bioengineered. 2021. PMID: 34047683 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical